Capital International Investors Vir Biotechnology, Inc. Transaction History

Capital International Investors

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.26 - $31.1 $43.9 Million - $74.7 Million	-2,402,282 Reduced 90.29%	258,400 $4.98 Million
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $31.8 Million - $44.6 Million	-1,668,834 Reduced 38.55%	2,660,682 $67.8 Million
Q1 2022 May 16, 2022	SELL	$21.19 - $40.01 $24.9 Million - $47.1 Million	-1,176,050 Reduced 21.36%	4,329,516 $111 Million
Q4 2021 Feb 14, 2022	SELL	$30.97 - $54.03 $99.7 Million - $174 Million	-3,218,090 Reduced 36.89%	5,505,566 $231 Million
Q3 2021 Nov 15, 2021	SELL	$34.9 - $54.54 $109 Million - $170 Million	-3,120,377 Reduced 26.35%	8,723,656 $380 Million
Q2 2021 Aug 16, 2021	BUY	$38.75 - $51.0 $824,212 - $1.08 Million	21,270 Added 0.18%	11,844,033 $560 Million
Q1 2021 May 14, 2021	BUY	$26.34 - $83.07 $13.7 Million - $43.4 Million	521,959 Added 4.62%	11,822,763 $606 Million
Q4 2020 Feb 12, 2021	BUY	$25.51 - $43.38 $451,782 - $768,259	17,710 Added 0.16%	11,300,804 $303 Million
Q3 2020 Nov 13, 2020	BUY	$28.28 - $53.6 $288 Million - $546 Million	10,188,789 Added 931.07%	11,283,094 $387 Million
Q1 2020 May 15, 2020	BUY	$12.04 - $60.2 $1.34 Million - $6.68 Million	111,005 Added 11.29%	1,094,305 $37.5 Million
Q4 2019 Feb 18, 2020	BUY	$11.83 - $15.85 $11.6 Million - $15.6 Million	983,300 New	983,300 $12.4 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.